Nesiritide Research Dosage: Published Protocol Reference
Nesiritide dosage references vary by route and study context. The database lists Intravenous bolus + infusion: 2 mcg/kg bolus, then 0.01 mcg/kg/min, Continuous infusion for up to 48 hours. These are research-context references, not a universal protocol.
Direct Answer
Nesiritide (Natrecor) is FDA-approved for acute decompensated heart failure with initial enthusiasm tempered by subsequent analysis showing limited mortality benefit and possible renal harm at higher doses. Current guidelines reserve it for symptom relief when other therapies are inadequate. It is a validated BNP analog with a well-characterized pharmacology, but its role in HF management has narrowed with evolving evidence.
- Evidence grade
- Level A
- Research status
- FDA Approved
- Category
- Healing & Recovery
- Best for
- Acute decompensated heart failure symptom management, BNP/natriuretic peptide pharmacology research
Research Dosage References
- <strong>Intravenous bolus + infusion</strong> - 2 mcg/kg bolus, then 0.01 mcg/kg/min - Continuous infusion for up to 48 hours - Bolus is optional. Infusion may be increased by 0.005 mcg/kg/min every 3 hours up to max of 0.03 mcg/kg/min. Monitor blood pressure closely.
Half-Life
~18 minutes.
Evidence Limits
Dosage entries are compiled from labels, published studies, and research-context references where available. For Nesiritide, the evidence grade is Level A, and the current research status is FDA Approved.
Safety Signals
- Hypotension is the most significant adverse effect - avoid in patients with SBP <100 mmHg
- Should not be used as primary therapy for cardiogenic shock
- Monitor renal function during infusion
- Limited long-term outcome data - use for symptom relief, not mortality reduction
Evidence Snapshot
| Evidence grade | Level A |
|---|---|
| Research status | FDA Approved |
| Best supported outcomes | Dyspnea Relief in Acute HF (Level A), Hemodynamic Improvement (Level A), and Renal Function Concerns (Level B) |
| Primary citation count | 3 |
| Last reviewed | 2026-04-04 |
Related Guides
How to Cite This Page
ExaminePeptides. "Nesiritide Research Dosage: Published Protocol Reference." Last reviewed 2026-04-04. https://examinepeptides.com/answers/nesiritide-research-dosage/
This static answer page is built for fast indexing and direct citation. It summarizes the matching full evidence review and links back to primary sources where the source database includes them.